* Interneuron Pharmaceuticals Inc., of Lexington, Mass., said researchers demonstrated that chronic administration of citicoline — a drug in Phase III stroke trials — increases the amount of phospholipid precursors in the brain. It is the first demonstration that human brain lipid metabolism can be modified with a drug, the company said.
* Organogenesis Inc., of Canton, Mass., said it is collaborating with Estee Lauder in a deal combining its living skin technology with the research strengths of the cosmetics company. Neither terms nor targets was disclosed.
* Repligen Corp., of Needham, Mass., and Amersham Pharmacia Biotech, of Uppsala, Sweden, said Repligen will be the primary supplier for 10 years of recombinant Protein A to APBiotech, a joint venture owned by Nycomed Amersham plc and Pharmacia and Upjohn Inc., of Bridgewater, N.J. Repligen said it expects aggregate revenues of more than $10 million from the deal.
* Allelix Biopharmaceuticals Inc., of Toronto, received approval to begin clinical testing of ALE-26015, its investigational drug for the treatment of dementia in patients with Alzheimer's disease. The Phase I study will be conducted by a clinical research organization based in the U.K.
* AltaRex Corp., of Waltham, Mass., said it retained First Marathon Securities Ltd., of Toronto, for a rights offering of C$2 million (US$1.2 million) and to act as lead agent for a proposed offering of up to C$15 million of convertible debentures special warrants to be issued on a private-placement basis.
* Biomatrix Inc., of Ridgefield, N.J., received approval from Australian regulatory authorities to market Synvisc, a viscosupplementation product for osteoarthritic knee pain. The company said it also has received approvals to market Synvisc, which is already approved in the U.S., in Malaysia, Singapore and Thailand.
* Boehringer Ingelheim GmbH, of Ingelheim, Germany, submitted a new drug application (NDA) to the FDA for Mobic, a once-daily cyclooxygenase inhibitor for the treatment of osteoarthritis. The drug is currently approved in 70 countries. The NDA was submitted by Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn.
* Glaxo Wellcome plc, of London, received FDA accelerated approval of Ziagen (abacavir sulfate) for use in combination with other drugs to treat HIV and AIDS. Ziagen is the first new drug in its class — nucleoside analogue reverse transcriptase inhibitors — to be approved in more than three years. (See BioWorld Today, June 26, 1998, p. 1.)
* Paracelsian, of Ithaca, N.Y., raised $250,000 through a placement of common stock. The money is expected to satisfy capital needs through commencement of a revenue stream. Paracelsian focuses on development and application of biofunctional assays.